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Molecular syndromic testing has received increased at-
tention in the last 5 to 10 years. However, clinical micro-
biology laboratories have been doing syndromic testing
for decades. Cultures for bacteria, viruses, fungi, and my-
cobacteria use methods (i.e., culture media, cell lines,
temperatures, incubation conditions) that allow the re-
covery of a wide breadth of organisms causing infection
at a particular body site; this is syndromic testing. Al-
though parasitology largely relies on microscopic exami-
nation of special stains, these techniques encompass de-
tection of the majority of human parasites described.
Combined, these methods have allowed providers to cast
a broad diagnostic net to determine etiologies of infec-
tious diseases.
In contrast to the syndromic approach of traditional
microscopic and culture-based methods, the initial mo-
lecular revolution in the clinical laboratory required pro-
viders to order each specific pathogen that they wanted to
detect bymolecular methods (i.e., orders for both entero-
viruses and herpes simplex viruses from cerebrospinal
fluid). The implementation of molecular detection for
viruses by real-time PCR was a gigantic leap forward in
terms of test sensitivity and time to result. However, mo-
lecular detection complicated test-ordering practices for
clinical providers. Instead of ordering a viral culture for a
patient with central nervous system disease, they now had
to list their pathogens of priority. With this approach, a
provider may not order an analyte for which the patient is
positive (1 ).
Molecular syndromic testing combines the advan-
tages of the approaches above: increased analytic sensitiv-
ity of molecular-based detection with the syndromic
“panel”-based approach of culture andmicroscopy. Food
and Drug Administration–cleared molecular panels now
exist for upper respiratory tract infections, pneumonia,
gastroenteritis, meningitis/encephalitis, sepsis and posi-
tive blood culture identification (1 ). The controversy lies
in how best to use syndromic panels and whether the tests
actually influence clinical management and improve pa-
tient outcomes. Although syndromic panels have sub-
stantially improved our ability to diagnose infectious dis-
eases, theses panels should be used cautiously and
thoughtfully. When combined with antimicrobial and
diagnostic stewardship efforts, syndromic tests are an im-
portant part of clinical decision-making, but their role in
improving patient outcomes is more difficult to assess.
The debate around molecular syndromic panels in-
cludes varying opinions on appropriate panel targets,
whether to use them as an initial test, in a testing algo-
rithm or even whether to use them at all (2, 3 ). Diagnos-
tic companies spend considerable time determining the
“best” panel, yet the final marketed panel will never ad-
dress every laboratory’s needs. Because of differences in
patient populations, prevalence of pathogens, and pro-
vider ordering patterns, there will not be a “one size fits
all” panel. In the quest to meet the clinical needs of a
majority of laboratories, manufacturers have potentially
extended some of the panels too far. By including rare
targets, or targets that are unique to certain patient pop-
ulations, the risk of medical errors increases owing to a
higher probability of false-positive results (analytically or
clinically). In addition, as the diagnostic limits of syn-
dromic panels are tested, we risk false-negative results due
to the limits of multiplexed analyses or specimen input
volume. The inability ofmany panels to hide targets from
reporting creates challenges for the laboratory, from cre-
ating the necessity to validate rare targets to testing and
reporting unnecessary targets in some clinical circum-
stances. That being said, creating customizable panels for
providers to order may lead to missed diagnoses. Further,
if the same test is used bymultiple facilities in a healthcare
system, but each institution has a customized panel, it
may create confusion and lead to medical errors. It is
important for clinicians, laboratorians, and manufactur-
ers alike to consider the guiding principle “first, do no
harm” when applying molecular syndromic panels di-
rectly to patient care. Careful consideration is needed to
determine the medical risks (false positives and false neg-
atives) and how best to mitigate those risks (i.e., addi-
tional testing, interpretive comments, hiding targets).
Molecular syndromic panels (in particular, respira-
tory and gastrointestinal) have also come under scrutiny
by third-party insurers andMedicare administrative con-
tractors. Specifically, some payers have determined that
large panel testing (5 targets) is not medically necessary
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for most patients. Reasons cited include the lack of spe-
cific treatment for many panel pathogens and the opin-
ion that panel pathogens do not cause overlapping syn-
dromes (4 ). Exceptions exist for critically ill or
immunosuppressed patients. Lack of coverage for Cur-
rent Procedural Terminology codes that encompass
larger syndromic panels may force laboratories to imple-
ment testing algorithms that are not necessarily best for
patient care or laboratory work flow. However, at the
heart of the noncoverage issue is whether there are
enough publicly available data to support the clinical util-
ity of syndromic panels (5 ).
There are many documented and hypothesized ben-
efits of molecular syndromic testing (Table 1). For most
panels, improvements in test performance relative to tra-
ditional methods have been documented, namely an in-
crease in analytical sensitivity and a decrease in time to
result. In some instances, analytic and clinical specificity
may be compromised. Demonstration of improvements
in patient care have primarily focused on antimicrobial
stewardship goals such as decreasing antimicrobial use
through viral respiratory panel testing or faster time to
targeted therapy for positive blood culture panel results.
Although many studies have investigated the effect of
rapid blood culture identification on patient care with
success, data demonstrating the effect of non–blood cul-
ture syndromic panel use on patient or cost outcomes are
sparse. It is challenging to design and perform studies
that measure improvements in patient care and clinical
outcomes; therefore, data supporting these hypothesized
benefits are still greatly needed (5 ). The outcome data
available are generally limited to a single institution or a
limited patient population (i.e., respiratory panels in pe-
diatrics). Further, reports on impact conflict in varying
patient populations. For example, Cybulski and col-
leagues (6 ) describe improved clinical sensitivity and tar-
geted/discontinued antimicrobial use with the imple-
mentation of a gastrointestinal panel, whereas Hitchcock
et al. (7 ) report the low yield of the same panel in adult
inpatients, and Axelrad et al. (8 ) show the decrease in
endoscopy, radiology, and antibiotic prescribing in a
combined inpatient/outpatient setting. Perhaps more
controversial is the analytical performance and potential
effect (both positive and negative) of a meningitis/en-
cephalitis panel, including false-negative Cryptococcus
and false-positive herpes simplex virus and Streptococcus
pneumoniae results (2, 9–11). The use of a meningitis/
encephalitis panel led to a reduced length of stay in 1
study (12 ), but another publication reported that the
meningitis/encephalitis panel’s rapid turnaround time
led to overuse of the test and approximately 25% of pos-
itive results were determined to be clinically insignificant
(13 ). These examples highlight the importance of keep-
ing the results obtained with syndromic panels in clinical
context and in the context of other laboratory results.
Although the availability of molecular syndromic panels
may allow testing at institutions that otherwise do not
have molecular capability, careful consideration is
needed to determine appropriate use of the test, includ-
ing consideration of pretest probability, contamination
monitoring, postanalytical interpretation, and the poten-
tial for additional laboratory testing for both positive and
negative results.
Although the initial adoption of syndromic molec-
ular panels was slow when only upper respiratory tract
panels were available, the pace of adoption and the
breadth of testing has markedly increased. Laboratories
of all sizes are now offering one or more molecular syn-
dromic tests. In addition, with the CLIA-waiver of syn-
dromic panels, the opportunity of bringing testing closer
to the patient is a reality. Major challenges exist when
offering molecular tests in a nonlaboratory setting. For
example, in addition to the usual challenges of point-of-
care testing, contamination (amplicon and environment)
is more likely to occur and less likely to be recognized
than if the test was performed in a laboratory; test orders
and results may not be documented in a patient’s elec-
tronic medical record; and the expertise of clinical micro-
Table 1 Potential benefits of molecular syndromic panel testing in comparison to conventional testing.
Test performance Patient care Clinical and cost outcomes
Detection of additional pathogens and
resistance genes
Decrease unnecessary testing Fewer healthcare-associated
infections
Improved analytic sensitivity Changes in antimicrobial therapy
(escalation, de-escalation, or
cessation)
Shorter hospital length of stay
Decreased time to result Effect on infection control
precautions (early removal or
implementation)
Fewer unnecessary admissions
and re-admissions
Near-patient testing using moderate-complexity
or CLIA-waived tests
Lower mortality
Reduced cost of care
biologists and infectious disease physicians may not be
readily accessible (14 ). However, these challenges are
worth addressing, because it may only be when testing is
done truly at the point of care that we will realize some of
the reputed benefits of syndromic testing.
Perhaps the most exciting investigational path for
syndromic testing is the combination of host expression
patterns and organism detection (15 ). By determining
whether a syndrome is likely infectious or noninfectious,
providers can be reassured when not prescribing antibi-
otics. Although biomarkers such as procalcitonin and
C-reactive protein are frequently used in the evaluation
of sepsis, pneumonia, and other infections, their use is
controversial and lacks clinical specificity. Some may ar-
gue that a syndromic test is not needed for some clinical
presentations (including respiratory and gastrointestinal)
because they are most commonly viral with no interven-
tion. However, if patients can be reassured that antibiot-
ics are not needed by providers who are empowered with
rapid, accurate, and inexpensive syndromic tests, we can
begin to reverse antibiotic overprescribing, which will aid
in our war on antimicrobial resistance.
As with the implementation of any new technology,
there are still more questions to be answered. Just because
we can test for so many targets, should we? Which pa-
tients would benefit most from syndromic testing? As
laboratorians, how do we educate clinical providers on
best ordering practices and result interpretation? For in-
stitutional economics, how is the return on investment in
molecular syndromic testing measured (i.e., length of
stay, readmission, decreased antibiotic use, or additional
testing)? How does a laboratory or healthcare system de-
termine the best panel for their institution? Should the
Food and Drug Administration require that all panels be
customizable via software?
Despite the caveats and questions highlighted here, I
am optimistic that the surge of syndromic panels, and the
associated competitive market, will continue to push di-
agnostics toward excellence. Our charge is to determine
and publish “real-world” performance characteristics, by
target, of syndromic panels.We need to provide postmar-
ket feedback to manufacturers on the clinical perfor-
mance of tests, and these data should be publicly avail-
able. We need to collaborate with industry and clinical
colleagues to ascertain the effect on patient care and out-
comes. We need to work with payers to define medical
necessity and reimbursement strategies. No test is perfect,
but if we are armed with the knowledge of true test per-
formance and clinical utility in specific patient popula-
tions, we can use these powerful tests in a safe and im-
pactful manner.
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